Ocular Therapeutix Valuation
| OCUL Stock | USD 9.77 0.12 1.21% |
At this time, the company appears to be undervalued. Ocular Therapeutix holds a recent Real Value of $10.66 per share. The prevailing price of the company is $9.77. Our model determines the value of Ocular Therapeutix from analyzing the company fundamentals such as Return On Equity of -0.73, shares outstanding of 157.22 M, and Operating Margin of (2.65) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ocular Therapeutix's valuation include:
Price Book 4.417 | Enterprise Value 1.2 B | Enterprise Value Ebitda (6.06) | Price Sales 25.8868 | Enterprise Value Revenue 19.5759 |
Undervalued
Today
Please note that Ocular Therapeutix's price fluctuation is somewhat reliable at this time. Calculation of the real value of Ocular Therapeutix is based on 3 months time horizon. Increasing Ocular Therapeutix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ocular stock is determined by what a typical buyer is willing to pay for full or partial control of Ocular Therapeutix. Since Ocular Therapeutix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ocular Stock. However, Ocular Therapeutix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.77 | Real 10.66 | Target 13.13 | Hype 9.79 | Naive 10.96 |
The intrinsic value of Ocular Therapeutix's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Ocular Therapeutix's stock price.
Estimating the potential upside or downside of Ocular Therapeutix helps investors to forecast how Ocular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ocular Therapeutix more accurately as focusing exclusively on Ocular Therapeutix's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ocular Therapeutix's intrinsic value based on its ongoing forecasts of Ocular Therapeutix's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ocular Therapeutix's closest peers.
Ocular Therapeutix Cash |
|
Ocular Valuation Trend
Knowing Ocular Therapeutix's actual value is paramount for traders when making sound investment determinations. Using both Ocular Therapeutix's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Ocular Revenue by Product
Ocular Therapeutix Total Value Analysis
Ocular Therapeutix is now anticipated to have valuation of 1.2 B with market capitalization of 1.58 B, debt of 83.39 M, and cash on hands of 134.54 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ocular Therapeutix fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.2 B | 1.58 B | 83.39 M | 134.54 M |
Ocular Therapeutix Investor Information
About 91.0% of the company shares are owned by institutional investors. The book value of Ocular Therapeutix was now reported as 0.79. The company recorded a loss per share of 1.29. Ocular Therapeutix had not issued any dividends in recent years. Based on the key measurements obtained from Ocular Therapeutix's financial statements, Ocular Therapeutix is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Ocular Therapeutix Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ocular Therapeutix has an asset utilization ratio of 23.19 percent. This suggests that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Ocular Therapeutix is more efficient with each dollar of assets it utilizes for everyday operations.Ocular Therapeutix Ownership Allocation
Ocular Therapeutix owns a total of 157.22 Million outstanding shares. The majority of Ocular Therapeutix outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Ocular Therapeutix to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Ocular Therapeutix. Please pay attention to any change in the institutional holdings of Ocular Therapeutix as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Ocular Therapeutix Profitability Analysis
The company reported the previous year's revenue of 58.44 M. Net Loss for the year was (80.74 M) with loss before overhead, payroll, taxes, and interest of (6.51 M).About Ocular Therapeutix Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Ocular Therapeutix. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Ocular Therapeutix based exclusively on its fundamental and basic technical indicators. By analyzing Ocular Therapeutix's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Ocular Therapeutix's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ocular Therapeutix. We calculate exposure to Ocular Therapeutix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ocular Therapeutix's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 53.2 M | 55.8 M | |
| Pretax Profit Margin | (1.38) | (1.45) | |
| Operating Profit Margin | (1.41) | (1.48) | |
| Net Loss | (1.38) | (1.45) | |
| Gross Profit Margin | 0.91 | 0.61 |
Ocular Therapeutix Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ocular Therapeutix does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 85.6 M |
Ocular Therapeutix Current Valuation Indicators
Ocular Therapeutix's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Ocular Therapeutix's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ocular Therapeutix, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ocular Therapeutix's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ocular Therapeutix's worth.When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.